Braz J Med Biol Res, August 2008, Volume 41 (8) 684-688 Evaluation of a 1-h 75-g oral glucose tolerance test in the diagnosis of gestational diabetes M.A.A. Campos 1,2, A.A.J. Reichelt 3, C. Façanha 4 ...

This paper presents a radio-frequency (RF) sensor to detect glucose oxidase. At the core of the proposed approach is a graphene film deposited on a gap connected to a split ring resonator. The ...

A unique design paradigm to form core–shell particles based on interfacial radical polymerization is described. The interfacial initiation system is comprised of an enzymatic reaction between glucose ...

A new study details the development of a nanoparticle-based system that delivers concentrated chemotherapy specifically to ...

Honey is a pantry staple. But does it expire or go bad? Here's the general health guidance to follow and tips to revive old, crystallized honey.

UCB announces positive results from GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency DisorderPhase 3 study met primary and key secondary clinical endpoints, marking the third developmental and ...

Honey produced by some species of Australian stingless bees possesses impressive bacteria- and fungi-killing properties, ...

To avoid the adverse consequences from abrupt increases in blood glucose, diabetic inpatients should be closely monitored. Using blood glucose data from type 2 diabetes patients, we propose a deep ...

Innovative needle-free technology empowers users to monitor glucose signals, oxygen saturation, and heart rate from home—without the discomfort or complexity of traditional tools.LOS ANGELES, June 24, ...

Glucose is normally filtered by the glomerulus, but is almost completely reabsorbed in the proximal tubule. Most reagent strips use a glucose oxidase/peroxidase method, which generally detects ...

This research is the first to reveal that the microbial-derived bile acid Trp-CA improves glucose homeostasis by activating MRGPRE. It provides a new potential drug target and therapeutic strategy for ...

REDWOOD CITY, Calif. - Corcept Therapeutics Incorporated (NASDAQ:CORT), a pharmaceutical company that has delivered an impressive 137% return to investors over the past year, announced Monday that its ...